Abstract
The assessment of HER2/c-erbB-2/neu (hereafter HER2) gene amplification and protein expression has become one of the central debating points in current breast cancer diagnosis and biology. The debate around whom to test, when testing should be offered, and, most importantly, which method to use is represented at most current conferences where breast cancer pathology is under discussion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Slamon, D. J., Clark, G. M., and Wong, S. G. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 217–227.
Coombs, L. M., Pigott, D. A., Sweeney, E., et al. (1991) Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer 63, 601–608.
Reles, A., Marx, D., Meden, H., et al. (1991) C-erb-b2 oncogene expression in ovarian cancers. Arch. Gynecol. Obstet. 250, 183–184.
Tyson, F. L., Boyer, C. M., Kaufman, R., et al. (1991) Expression and amplification of the her-2/neu (c-erb-2) protooncogene in epithelial ovarian-tumors and cell-lines. Am. J. Obstet. Gynecol. 165, 640–646.
Albino, A. P., Jaehne, J., Altorki, N., et al. (1995) Amplification of HER-2/neu gene in human gastric adenocarcinomas. Eur. J. Surg. Oncol. 21, 56–60.
Underwood, M. A., Bartlett, J., Reeves, J., et al. (1994) C-erbB2 gene amplification as a molecular marker in bladder-cancer. Cancer Res. 81, 1822–1822.
Slamon, D. J., Godolphin, W., Jones, L. A., et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712.
Revillion, F., Bonneterre, J., and Peyrat, J. P. (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 34, 808.
Ross, J. S. and Fletcher, J. A. (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16, 413–428.
Andrulis, I. L., Bull, S. B., Blackstein, M. E., et al. (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J. Clin. Oncol. 16, 1340–1349.
Dalifard, I., Daver, A., Goussard, J., et al. (1998) p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification. Bioorg. Med. Chem. Lett. 1, 855–861.
Press, M. F., Bernstein, L., Thomas, P. A., et al. (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894–2904.
Piffanelli, A., Dittadi, R., Catozzi, L., et al. (1996) Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res. Treat. 37, 267–276.
Press, M. F. (1990) Oncogene amplification and expression. Importance of methodologic considerations. Am. J. Clin. Pathol. 94, 240–241.
Press, M. F., Hung, G., Godolphin, W., et al. 1994. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohis-tochemical studies of oncogene expression. Cancer Res. 54, 2771–2777.
Goldenberg, M. M. (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309–318.
Bartlett, J. M. S., Mallon, E. A., and Cooke, T. G. (2003) The clinical evaluation of HER2 status, which test to use? J. Pathol. 199, 411–417.
Giai, M., Roagna, R., Ponzone, R., et al. (1994) Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res. 14, 1441–1450.
Rosen, P. P., Lesser, M. L., Arroyo, C. D., et al. (1995) Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75, 1320–1326.
Carlomagno, C., Perrone, F., Gallo, C., et al. (1996) c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14, 2702–2708.
Muss, H., Berry, D., and Thor, A. (1999) Lack of interaction of tamoxifen (T) use and ErbB-2/Her-2/Neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, dooxrubicin and fluorouracil (CAF) in node positive primary breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 18, 68A (abstract).
Paik, S., Bryant, J., Park, C., et al. (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90, 1361–1370.
Ravdin, P. M., Green, S., Albain, V., et al. (1998) Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc. Am. Soc. Clin. Oncol. 17, 97A (abstract).
Thor, A. D., Berry, D. A., Budman, D., et al. (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 90, 1346–1360.
Arber, D. A. (2000) Molecular diagnostic approach to non-Hodgkin’s lymphoma. J. Mol. Diagn. 2, 178–190.
Mitchell, M. S. and Press, M. F. (1999) The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer. Semin. Oncol. 26, 108–116.
Pauletti, G., Godolphin, W., Press, M. F., et al. (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13, 63–72.
Bartlett, J. M. S., Reeves, J., Stanton, P., et al. (2001) Evaluating HER2 amplification and overexpression in breast cancer. J. Pathol. 195, 422–428.
Ellis, I. O., Dowsett, M., Bartlett, J., et al. (2000) Recommendations for HER2 testing in the UK. J. Clin. Pathol. 53(12), 890–892.
Edwards, J., Krishna, N. S., Mukherjee, R., et al. (2001) Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU Int. 88, 633–637.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Bartlett, J.M.S., Forsyth, A. (2004). HER2 FISH in Breast Cancer. In: Roulston, J.E., Bartlett, J.M.S. (eds) Molecular Diagnosis of Cancer. Methods in Molecular Medicine, vol 97. Humana Press. https://doi.org/10.1385/1-59259-760-2:089
Download citation
DOI: https://doi.org/10.1385/1-59259-760-2:089
Publisher Name: Humana Press
Print ISBN: 978-1-58829-160-8
Online ISBN: 978-1-59259-760-4
eBook Packages: Springer Protocols